What Flow Cytometry Offers That Other Techniques Cannot
Flow cytometry measures multiple physical and chemical characteristics of individual cells as they pass, one by one, through a laser beam. Each cell scatters light in a pattern determined by its size and internal complexity, and emits fluorescence from labelled antibodies or other probes bound to specific markers on its surface or inside the cell. A modern flow cytometer can measure ten, fifteen, or more parameters simultaneously on each cell, generating a dataset that describes the phenotype and functional state of thousands of individual cells in a single sample.
For clinical trials that involve the immune system, this single-cell resolution is what makes flow cytometry irreplaceable. Bulk methods such as ELISA or gene expression arrays describe the average behaviour of a cell population. Flow cytometry resolves that population into its constituent subsets, revealing changes in the relative proportions of T cell subsets, NK cell activation states, or myeloid cell phenotypes that would be invisible in aggregate data.
Clinical Applications of Flow Cytometry
Immunophenotyping for Immunotherapy Trials
Immune checkpoint inhibitors, CAR-T cell therapies, bispecific antibodies, and other immunotherapy modalities all act by modifying the immune system. Understanding how they change the composition and activation state of immune cell populations in peripheral blood or tumour tissue is essential for interpreting clinical responses and adverse events. Flow cytometry panels for immunotherapy trials typically characterise T cell subsets including CD4, CD8, regulatory T cells, and exhaustion markers, as well as NK cells and myeloid populations.
Pharmacodynamic Monitoring
Flow cytometry is widely used to measure the pharmacodynamic effects of biologic drugs that target immune cell populations. For a drug targeting CD20-positive B cells, flow cytometry provides direct evidence of B cell depletion in peripheral blood. For a drug intended to expand a specific T cell population, multi-parametric immunophenotyping demonstrates the intended pharmacological effect and supports dose selection.
Minimal Residual Disease (MRD) Assessment
In haematological malignancies including leukaemia and multiple myeloma, flow cytometry is used to detect residual tumour cells at levels below the threshold of morphological assessment. Multi-parametric MRD panels using eight or more markers can detect one tumour cell in ten thousand or more normal cells, providing a sensitive endpoint for assessing depth of response to treatment.
Building a Validated Multi-Parametric Panel
| Development Step | Purpose | Key Considerations |
| Panel design | Select fluorochrome-antibody combinations that minimise spectral overlap and maximise signal resolution | Use brightest fluorochromes for low-density targets; apply compensation controls for every fluorochrome in the panel |
| Titration optimisation | Determine optimal antibody concentration for each reagent | Under-titration loses signal; over-titration increases background; titrate in the intended matrix |
| Specificity testing | Confirm each antibody detects the intended target | Use positive and negative control cell populations with known phenotype |
| Sensitivity / LLOQ | Determine the lowest detectable frequency of positive cells | Critical for rare cell populations and MRD applications |
| Inter-operator and inter-instrument precision | Demonstrate reproducibility across analysts and instruments | Use standardised bead-based calibration; include reference samples across runs |
| Fit-for-purpose validation | Demonstrate panel performance meets requirements for intended use | Scope determined by data criticality; follow EuroFlow or ISAC guidelines as appropriate |
Practical Considerations for Clinical Sample Handling
Flow cytometry results are sensitive to pre-analytical variables including time from blood collection to processing, storage temperature, and the use of anticoagulants. Whole blood samples for immunophenotyping are typically processed within four to six hours of collection, using lyse-no-wash protocols that minimise cell activation and loss. For clinical trials where samples are collected at remote sites and shipped to a central laboratory, the pre-analytical handling conditions must be validated to demonstrate that the analytical results are not affected by the transport time and conditions.
Ardena’s clinical team at Assen works with clinical operations teams to design sample handling procedures that are practical for site staff while ensuring data quality at the central laboratory. Stability data supporting the validated shipping conditions is documented and available for regulatory review.
Ardena’s Flow Cytometry Capabilities
Ardena’s flow cytometry laboratory in Assen operates multi-laser instruments capable of panels up to fifteen or more parameters, with dedicated capacity for clinical trial sample analysis. The team develops and validates multi-parametric immunophenotyping panels, MRD panels, and functional assays including intracellular cytokine staining and proliferation assays.
Flow cytometry services at Ardena are integrated with the wider bioanalytical platform, allowing immune cell data to be interpreted alongside PK, PD, and immunogenicity data from the same study, providing the multi-dimensional dataset that characterises the immune pharmacology of complex therapeutics.
